Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
G+FLAS has constructed an immunogenic recombinant vaccine candidate expressed in transgenic plants based on its own plant-based protein production platform.
Lead Product(s): Immunogenic recombinant vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2020